Influvactetra

Influenza virus vaccine (B/Phuket/3073/2013-like, B/Austria/1359417/202), the active ingredient in Influvactetra, is a vaccine presented as an injectable solution for intramuscular or subcutaneous use. It provides active immunity to prevent influenza B infections in individuals at risk. The vaccine contains antigens from two representative influenza B strains, stimulating the body’s immune response to produce protective antibodies. GNH USA supplies Influvactetra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled manufacturing, regulatory compliance, and reliable cold‑chain logistics for global distribution.

Influvactetra is indicated for immunization against influenza B viruses, helping to reduce disease incidence. - Seasonal influenza B: reduces the risk of laboratory‑confirmed influenza B infection in the general population. - Outbreak control: contributes to limiting the spread of influenza B during community or institutional outbreaks. - High‑risk groups: provides added protection for elderly individuals, immunocompromised patients, and those with chronic medical conditions.

Influvactetra may cause a range of post‑vaccination reactions, most of which are mild and self‑limiting.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Low‑grade fever: temperature rise up to 38°C. - Headache: transient mild headache. - Fatigue: temporary feeling of tiredness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder with muscle weakness. - High fever or seizures: uncommon but may occur, especially in children.

Before administering Influvactetra, consider the following precautions to ensure safe use. - Allergy assessment: screen for severe allergy to egg proteins or vaccine components. - Age restriction: not recommended for children younger than six months. - Immunocompromised patients: evaluate risk‑benefit, as response may be reduced. - Pregnancy and lactation: consult a healthcare professional before use. - Concomitant vaccines: separate administration from live attenuated vaccines by at least four weeks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Influvactetra can interact with other agents that affect immune response or vaccine efficacy.

Major Interactions (Avoid): - Live attenuated vaccines: avoid simultaneous administration to prevent interference. - Immunoglobulin therapy: may neutralize vaccine antigens, reducing effectiveness.

Moderate Interactions (Monitor Closely): - Antipyretic analgesics: may mask fever, monitor for underlying reactions. - Corticosteroids: high‑dose steroids can blunt antibody response, assess timing. - Antiviral medications: certain antivirals may interfere with vaccine virus replication, consider scheduling.